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immunodeficiency virus (SIV)-specific CD8+
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Background
CD8+ cytotoxic T lymphocytes (CTL) are a critical
component of antiviral immunity and play an important
role in the control of lentiviral infection.
Methods
We have developed an in vivo CTL assay to directly
measure the killing capacity of MHC-restricted SIV-spe-
cific CTL in rhesus macaques (RM). In order to evaluate
the in vivo efficacy of different epitope-specific CTL, we
compared the in vivo killing capacity of Mamu-A*02-
restricted Nef YY9 and Gag GY9 CD8+ T lymphocytes
in three RM vaccinated with a recombinant HSV prime/
DNA boost SIV vaccine regimen.
Results
Tetramer frequencies of Mamu-A*02-restricted Nef YY9-
specific CD8+ T-cells were at least 10-fold higher than
Mamu-A*02-restricted Gag GY9-specific CD8+ T-cells
in individual animals both pre- and post-challenge. Prior
to SIV challenge, both CTL populations showed poor
and incomplete killing (22-35%) of target cells over
18 hours. Seven weeks post-challenge, there was a
marked increase in the CTL killing capacity of both Nef
YY9 and Gag GY9-specific CTL with 26-38% killing
occurring over the first two hours and up to 100% killing
over 18 hours. Surprisingly, Gag GY9-specific CTL con-
sistently showed equivalent or greater in vivo killing
when compared to Nef YY9-specific CTL even though
the percentages of IFN-g secreting and degranulating
cells upon peptide stimulation were comparable.
Conclusion
These data suggest that epitope specificity rather than
tetramer frequency determines the ability of SIV-specific
CTL to kill infected cells. Taken together, these data
may have important implications for the development of
a successful HIV vaccine.
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